SEC Form 4 · accession 0001179110-17-005299
INVIVO THERAPEUTICS HOLDINGS CORP. · NVIV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher McNulty
Officer — Chief Financial Officer
Period of report
Mar 29, 2017
Accepted (ET)
Mar 31, 2017 · 3:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001292519
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy)F1 | $4.00 | Mar 29, 2017 | A | 29,973 | A | — | Mar 29, 2027 | Common Stock | 29,973 | 29,973 | D |
Explanation of responses
- F1This option vests as to 25% of the shares on March 29, 2018, and the remaining shares vest thereafter on a monthly basis in 36 equal monthly installments.